Author Archives: admin


Stem Cell Clinic > Articles by: admin

AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX advances AML drug with $35M D round – Endpoints News

By Stem Cell Clinic

Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattles Wells Fargo Building.

Louis Picker and Klaus Frh, professors at Oregon Health & Science University, had by then spent 5 years running around the country in search of funding for their startup, TomegaVax, and Frh, at least, was nearing wits end. The Gates Foundation was interested but told them they needed other investors. Investors told them to come back with more data, pharmaceutical executives said theyre in the wrong game too little money to be made fighting infectious disease. Still, a well-connected board member named Bob More landed them a meeting with the coveted venture capitalist, and so, in a narrow conference room overlooking the Puget Sound, Picker prepared to again explain the idea he had spent 15 years on: re-engineering a benign microbe into the first vaccines for HIV and better ones for hepatitis and tuberculosis.

This lightbulb went on his head, Picker recalled in a recent interview. Most of them just didnt get it. And Bobs hit.

By that point, Nelsen was more than just a venture capitalist. Scraggly and greying but no less opinionated at 52, he was mobbed at biotech conferences, having earned a reputation for crass wisdom and uncanny foresight, for making big bets on big ideas that changed medicine. Those ideas included DNA sequencing, which he first cut a check for in the 90s, and leveraging the immune system to tackle cancer. He earned millions making billion-dollar companies.

Yet for years he had harbored an almost singular obsession: I hate viruses, he told Forbes in 2016. He told me he was pissed off at them. The obsession drove him to his first biotech investment in 1993, for an inhalable flu vaccine approved a decade later and still in use. And it drove him to invest in CAR-T as a potential cure for HIV, years before it proved a wildly effective treatment for some cancers.

Now, listening to Picker talk about T cells and antibodies and the curious biology of cytomegalovirus, Nelsen began wondering if it was time for another bet. Pickers technology was not only promising, he reasoned, it could be the basis of a company that changed how researchers approached viruses. Instead of trying to come up with an antidote for every pathogen, you could do what cancer researchers had learned to do, and harness the immune system to do the work for you.

This wasnt a popular opinion at the time. Its like the least trendy idea in the world, Nelsen told me. People would say, Why the hell are you going into infectious disease?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Visit link:
AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX advances AML drug with $35M D round - Endpoints News

After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything – Endpoints News

By Stem Cell Clinic

Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattles Wells Fargo Building.

Louis Picker and Klaus Frh, professors at Oregon Health & Science University, had by then spent 5 years running around the country in search of funding for their startup, TomegaVax, and Frh, at least, was nearing wits end. The Gates Foundation was interested but told them they needed other investors. Investors told them to come back with more data, pharmaceutical executives said theyre in the wrong game too little money to be made fighting infectious disease. Still, a well-connected board member named Bob More landed them a meeting with the coveted venture capitalist, and so, in a narrow conference room overlooking the Puget Sound, Picker prepared to again explain the idea he had spent 15 years on: re-engineering a benign microbe into the first vaccines for HIV and better ones for hepatitis and tuberculosis.

This lightbulb went on his head, Picker recalled in a recent interview. Most of them just didnt get it. And Bobs hit.

By that point, Nelsen was more than just a venture capitalist. Scraggly and greying but no less opinionated at 52, he was mobbed at biotech conferences, having earned a reputation for crass wisdom and uncanny foresight, for making big bets on big ideas that changed medicine. Those ideas included DNA sequencing, which he first cut a check for in the 90s, and leveraging the immune system to tackle cancer. He earned millions making billion-dollar companies.

Yet for years he had harbored an almost singular obsession: I hate viruses, he told Forbes in 2016. He told me he was pissed off at them. The obsession drove him to his first biotech investment in 1993, for an inhalable flu vaccine approved a decade later and still in use. And it drove him to invest in CAR-T as a potential cure for HIV, years before it proved a wildly effective treatment for some cancers.

Now, listening to Picker talk about T cells and antibodies and the curious biology of cytomegalovirus, Nelsen began wondering if it was time for another bet. Pickers technology was not only promising, he reasoned, it could be the basis of a company that changed how researchers approached viruses. Instead of trying to come up with an antidote for every pathogen, you could do what cancer researchers had learned to do, and harness the immune system to do the work for you.

This wasnt a popular opinion at the time. Its like the least trendy idea in the world, Nelsen told me. People would say, Why the hell are you going into infectious disease?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Read the rest here:
After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything - Endpoints News

Global EPrescription Market Research Along With COVID-19 Impact Analysis, Advancement and Outlook 2027|eclinicalworks, Henry Schein, Inc., Drfirst,…

By Gene Therapy Clinics

Eprescription marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 4,581.45 million by 2027 growing at a CAGR of 21.8% in the above-mentioned forecast period. The increasing focus on the lessening of fraud & abuse of controlled substances has been directly impacting the growth of eprescription market.

Some of the key players profiled in the report areHealth Fusion, Inc., EPIC Systems Corporation, GE Healthcare, eclinicalworks, Henry Schein, Inc., Drfirst, Relayhealth, CPSI, Surescripts, Cerner Corporation, Quality Systems, Inc., Medical Information Technology, Inc., Allscripts Healthcare LLC, Athenahealth, eClinicalWorks and Aprima Medical Software, Inc., among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately. Download Sample PDF Copy of Report Along With Graphs &[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-eprescription-market

EPrescription market document is an ideal guide to attain an information or key data about market, emerging trends, product usage, and motivating factors for customers, customer preferences, competitor strategies, brand positioning, and customer behaviour. This market research report delivers an analytical measurement of the main challenges faced by the business currently and in the upcoming years. Geographical areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa are also considered for the market analysis. In addition, the EPrescription market research report contains company profile, product specifications, production value, market shares and contact information of manufacturers or companies.

North America dominates the eprescription market due to the high number of government initiatives and encouragement in the region.

To know more about the study @https://www.databridgemarketresearch.com/reports/global-eprescription-market

Global EPrescription Market Drivers & Restraints:

The increasing focus on the lessening of fraud & abuse of controlled substances has been directly impacting the growth of eprescription market.

Rising government initiatives & incentive programs is expected to have a significant impact on the eprescription market in the forecast period of 2020 to 2027. Other impactful reasons for the market growth are increased usage of eprescription has been the increased focus on reducing medication errors, need to restrict rising healthcare costs and high adoption in healthcare industry due to its benefits such as better patient safety.

Moreover, rising government support along with increasing implementation of electronic prescribing and medication administration system will further cater ample opportunities that will lead to the growth of eprescription market in the above mentioned forecast period.

High cost of employment and security & workflow issues will hamper the growth of the eprescription market in the forecast period of 2020 to 2027. Lack of technological awareness will pose as a challenge towards the growth of the eprescription market in the above mentioned forecast period.

To register for digital conference click here @https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Segmentation: Global EPrescription Market

Eprescription market is segmented on the basis of product, usage mode, mode of delivery and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the eprescription market is segmented into solutions and services. Solutions segment is further segmented into integrated solutions and standalone solutions.

On the basis of usage mode, the eprescription market is segmented into handheld device and computer-based devices.

Based on mode of delivery, the eprescription market is segmented into web & cloud-based solutions and on-premise solutions.

Eprescription market has also been segmented based on the end-user into clinics, physicians, pharmacies and hospitals.

Objective of the Report

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-eprescription-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email:[emailprotected]

Read the original here:
Global EPrescription Market Research Along With COVID-19 Impact Analysis, Advancement and Outlook 2027|eclinicalworks, Henry Schein, Inc., Drfirst,...

Global Blood Screening Market Size, Share, Industry Growth Survey by Types, Applications and Top Key Players Enzo Biochem Inc., Meridian Bioscience,…

By Gene Therapy Clinics

Data Bridge Market Research recently released a research report on the Blood Screening analysis, which studies the Blood Screening industry coverage, current market competitive status, and market outlook and forecast by 2027.This is an insightful research report that highlights key market patterns and market drivers in the present circumstance and offers on the ground bits of knowledge. The report likewise displays examination of market size, offer, and development, patterns, and value structure, measurable and definite information of the overall business.

Blood screening marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow with a CAGR of 5.75% in the above-mentioned forecast period.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-screening-market

Some of the prominent participants operating in this market are Enzo Biochem Inc., Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc., BioMrieux SA, Beckman Coulter, Inc., Abbott , F. Hoffmann-La Roche Ltd , Cepheid , GRIFOLS INTERNATIONAL, S.A. , Siemens AG , Ortho Clinical Diagnostics , Immucor, Inc., Hologic Inc., among others.

To register for digital conference click here @ https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Segmentation:Global Blood Screening Market

By Products & Services

(Reagents & Kits, Instruments, Software & Services),

Technology

(Enzyme-Linked Immunosorbent Assay, Rapid Tests, Next-Generation Sequencing, Nucleic Acid Test, Western Blot Assay, Others),

Disease Type

(Oncology, Diabetes Mellitus, Cold & Flu, Cholesterol, Infectious Diseases, Respiratory Diseases, HIV/AIDS, Others),

End User

(Diagnostic Centers, Blood Bank, Hospitals, Clinics, Ambulatory Surgical Centers),

Geography

(North America, Europe, Asia-Pacific, South America, Middle East & Africa)

Global blood screening market is categorized based on basis of products & services, technology, disease type and end user.

Drivers:Global Blood Screening Market

RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS:

Blood transfusion is an essential component of the health care field. It helps in saving millions of lives every year in both cases of routine and emergency conditions. Below mentioned are some of the statistics for blood donation and blood donors:

According to the World Health Organization (WHO), in 2017, it was reported that 112.5 million blood donations were collected from worldwide in which approximately half of the blood was collected from developed countries.

According to the World Health Organization (WHO), in 2017, it was reported that in 1000 people, the blood donation rate was 32.1 from high-income countries, 14.9 in upper-middle-income countries, 7.8 in lower-middle-income countries and 4.6 in low-income countries.

According to Australia Red cross blood service, 606,000 donors are there in Australia which are in 1,000 locations such as collection centres for blood donation available.

RISING PREVALENCE IN NUMBER OF DISEASES:

The prevalence of diseases and conditions such as Tuberculosis, HIV infection, Intestinal nematodes, diabetes mellitus, respiratory diseases, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and many others have increased considerably over a period of time. As numbers of diseases are increasing there is requirement for blood screening and diagnosis for further treatment of diseases.

According to WHO, alpha and beta thalassaemias are found to be the most common inherited single-gene disorders around the world. This disorder is with the highest prevalence with malaria at the places where it is endemic.As per the study conducted in Iran, it was estimated that approximately 8,000 pregnancies with risk takes place every year.

In 2016, according to Centers for Disease Control and Prevention (CDC), at the end of 2015, it was estimated 1.1 million persons with age 13 or older were suffering from HIV infection in the U.S. with an estimation of 162,500 (15.0%) persons whose infections had not been diagnosed.

In February 2018, according to verywell health, in South Africa 5,600,000 of people were estimated with HIV in 2009. In the total population of 53 million, the HIV prevalence for South Africa is found to be 10.6%.

Read Full Report @https://www.databridgemarketresearch.com/reports/global-blood-screening-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:[emailprotected]

Read the original here:
Global Blood Screening Market Size, Share, Industry Growth Survey by Types, Applications and Top Key Players Enzo Biochem Inc., Meridian Bioscience,...

National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial – Business Wire

By Stem Cell Treatment

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm, announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), which is part of the United States Government Department of Health and Human Services (HHS) as represented by the Division of Microbiology and Infectious Diseases (DMID), and Humanigen have executed a clinical trial agreement for lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, as an agent to be evaluated in the NIAID-sponsored Big Effect Trial (BET) in hospitalized patients with COVID-19.

BET will help advance NIAIDs strategic plan for COVID-19 research, which includes conducting studies to advance high-priority therapeutic candidates.1 Identification of agents with novel mechanisms of action for therapy is a strategic priority.

This trial builds on initial data from NIAIDs Adaptive COVID-19 Treatment Trial (ACTT) that demonstrated Gileads investigational antiviral, remdesivir, may improve time to recovery in hospitalized patients with COVID-19. BET will evaluate the combination of lenzilumab and remdesivir on treatment outcomes versus placebo and remdesivir in hospitalized COVID-19 patients. The trial is expected to enroll 100 patients in each arm of the study with an interim analysis for efficacy after 50 patients have been enrolled in each arm.

We have been encouraged by the lenzilumab efficacy and safety data demonstrated in the compassionate use series in COVID-19 patients and are thrilled that NIH selected lenzilumab to be part of its Big Effect Trial, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. With data from the BET and our ongoing Phase III study, we will have data from approximately 500 hospitalized COVID-19 patients.

Experience with SARS-CoV-2 indicates that infection of the respiratory tract is rapid and damage is primarily mediated by the host inflammatory response. These conditions may make it difficult to modify COVID-19 with a pathogen-directed therapeutic. Host-directed strategies that target the immune response may exert additional therapeutic benefit. Having previously published data demonstrating the ability of lenzilumab to prevent and/or treat cytokine storm, Humanigen believes lenzilumab may be synergistic in the treatment of patients with COVID-19 when used in combination with a direct-acting antiviral, like remdesivir, given the differing mechanisms of action.

More details on Humanigens programs in COVID-19 can be found on the companys website at http://www.humanigen.com under the COVID-19 tab, and details of the US Phase III potential registration study can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04351152.

1 NIAID Strategic Plan for COVID-19 Research FY2020 FY2024. National Institute of Allergy and Infectious Diseases. April 22, 2020. https://www.niaid.nih.gov/sites/default/files/NIAID-COVID-19-Strategic-Plan-2020.pdf.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

View original post here:
National Institutes of Health Selects Humanigen's Lenzilumab for its COVID-19 Big Effect Trial - Business Wire

Therapeutic Solutions International Files Patent on Ability of QuadraMune Ingredient Pterostilbene to Reduce Inflammation while Stimulating Brain…

By Stem Cell Medicine

OCEANSIDE, Calif., July 28, 2020 /PRNewswire/ --Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported new data demonstrating that the blueberry derived compound pterostilbene possesses numerous brain protective and potentially brain regenerative activities. Pterostilbene is one of four ingredients which comprise QuadraMune, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19. Information on the clinical trial can be found on the Government Clinical Trials website https://clinicaltrials.gov/ct2/show/NCT04421391.

"These new data confirm previous findings published on pterostilbene and also reveal novel therapeutic properties of this naturally occurring nutrient," said Dr. James Veltmeyer, Chief Medical Officer of the Company and Voted Top Doctor of San Diego. "By continually investigating mechanisms of action of our products, our ambition is to ensure we have support of the top medical and scientific leaders. In my opinion, many times, it does not matter how good your product is, what matters is that you have scientific basis for why it works. This is especially important in the current age of molecular medicine."

The data disclosed by the Company indicates:

a) pterostilbene suppresses inflammatory cytokines TNF-alpha, IL-1 beta and IL-6;

b) pterostilbene inhibits death of neurons caused by inflammatory mediators;

c) pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1, and FGF-2; and

d) pterostilbene allows/enhances proliferation of endogenous brain stem cells.

"The importance of possessing a deep scientific understanding of your product can be seen in the example of nutraceuticals which ended up obtaining regulatory clearance as drugs," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "For example, Lovaza and Vascepa are both fish oil based products which have been developed scientifically and FDA approved through clinical trials. Lovaza, which is sold by GSK, had sales of approximately 1 billion per year and is used for reduction of triglycerides.1 Vascepa, sold by Amarin, had sales in 2019 of 410 million and is used to prevent heart attacks.2 We believe that similar developmental pathways may be possible with several of our existing products."

The Company is currently pursuing FDA clearance for its cell therapy produce StemVacs, for which an IND number was previously granted. The Company's in-licensed stem cell, the JadiCell has FDA clearance for other indications.

About Therapeutic Solutions International, Inc.Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, our public forum is https://board.therapeuticsolutionsint.com/.

1http://www.pmlive.com/pharma_news/teva_launches_first_generic_of_gsks_lovaza_in_us_559273 2https://www.fool.com/investing/2020/01/07/amarin-reports-preliminary-vascepa-sales-projects.aspx

Therapeutic Solutions International, Inc. [emailprotected]

SOURCE Therapeutic Solutions International

therapeuticsolutionsint.com

See the article here:
Therapeutic Solutions International Files Patent on Ability of QuadraMune Ingredient Pterostilbene to Reduce Inflammation while Stimulating Brain...

Cell and Gene Therapy Tools, and Reagents: Global Markets – PRNewswire

By Stem Cell Treatment

NEW YORK, July 27, 2020 /PRNewswire/ -- Report Scope: The scope of this study encompasses an investigation of the markets cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors.The analyst examines each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years.

Read the full report: https://www.reportlinker.com/p05938974/?utm_source=PRN

Technological issues, including the latest trends, are discussed. The analyst examined the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

Report Includes: - 77 data tables - An overview of the global market for immunoassay-based cell and gene therapy tools, and reagents within the life sciences industry - Analyses of the global market trends, with data corresponding to market size for 2017-2019, and projections of compound annual growth rates (CAGRs) through 2024 - Information about in vitro diagnostics (IVD), its background and importance of IVD testing - Discussion on prevalence of infectious disease, metabolic disorders and chronic ailments as drivers of immunoassay testing market - Description of recent technologies such as chemiluminescent immunoassays (CLIA), fluorescent immunoassays, multiplex assays and rapid diagnostic technologies - Evaluation of market potential for immunoassay-based cell and gene therapy tools and reagents, current market size and market forecast, and market share analysis of the leading players engaged - Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology - Company profiles of the key market participants, including Bio-Rad Laboratories, Cytiva Life Sciences, Luminex Corp., Millipore Sigma, Thermo Fisher Scientific and STEMCELL Technologies

Reasons for Doing this Study: Gene and cell therapy are emerging as important tools to treat human health.Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers.

The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene- based diseases.As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging.

This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

Read the full report: https://www.reportlinker.com/p05938974/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Continue reading here:
Cell and Gene Therapy Tools, and Reagents: Global Markets - PRNewswire

Global Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 2020-2024| Increase in Awareness of Stem Cell Therapy to Boost Market…

By Stem Cell Treatment

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global stem cell therapy market size and it is poised to grow by USD 588.22 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

An increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Stem Cell Therapy Market 2020-2024: Segmentation

Stem Cell Therapy Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43432

Stem Cell Therapy Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The stem cell therapy market report covers the following areas:

This study identifies the limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Stem Cell Therapy Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer Landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Originally posted here:
Global Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 2020-2024| Increase in Awareness of Stem Cell Therapy to Boost Market...

Enthera Pharmaceuticals Raises 28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and Inflammatory Bowel Disease -…

By Stem Cell Treatment

MILAN, Italy--(BUSINESS WIRE)--Enthera Pharmaceuticals (Enthera), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a 28 million Series A financing round.

The Series A was co-led by seed investor Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and incoming investor AbbVie, with further investment from the JDRF T1D Fund (the venture capital fund of JDRF) and several Italian investors including a group coordinated by Banor SIM, a group coordinated by Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners SGR. The 28 million raised is the largest VC-backed Series A funding round for an Italian biotechnology company to date.

The Series A marks AbbVies first venture investment into an Italian company. Enthera was also the first European investment of the JDRF T1D fund, who previously invested in the Company during its 4 million seed extension funding round in 2018.

The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Entheras lead candidate. Ent001 is the only drug in development with the potential to restore the pancreatic beta cell compartment in type 1 diabetes as well as the original intestine structure in inflammatory bowel disease, in order to re-establish organ function. The funds will also be used to further develop Entheras pipeline.

Commenting on the successful Series A financing, Giovanni Amabile, CEO of Enthera, said: Having renowned investors Sofinnova Partners, AbbVie and JDRF T1D Fund choosing to support us on our journey is great validation of our company strategy and scientific method, and gives credit to the innovative science that is currently underway in Italy.

We have a revolutionary approach that offers a new perspective for intractable diseases such as type 1 diabetes and inflammatory bowel disease, and the funds raised will enable us to accelerate our lead program Ent001 to clinical proof-of-concept. Through this and the development of our wider pipeline, we have the opportunity to bring real hope to patients in need and to provide effective and safe treatments.

Graziano Seghezzi, Managing Partner of Sofinnova Partners, who co-seeded the company, stated: Entheras Series A financing is a fantastic milestone enabled by the leadership of Giovanni who, since his arrival in the company, has expanded its activities into novel therapeutic areas. This is also an opportunity for us to applaud BiovelocITAs role in transforming the breakthrough science originating from Paolo Fiorina and his team into a full-fledged enterprise. Enthera is a salient example of what can be achieved when the critical components of a biotech ecosystem are brought together to accelerate innovation in Italy: World-class science, experienced management, and dedicated financial capital.

Margarita Chavez, Managing Director of AbbVie Ventures and new addition to the Enthera Board of Directors, added: AbbVie Ventures investment in Entheras Series A demonstrates our confidence in the team and their unique approach to treating underserved autoimmune disorders. I look forward to working with Giovanni and rest of the team as we drive the Company and its innovation forward.

Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca DAddio. The Company is the first spin-off of the Italian biotech accelerator BiovelocITA, founded by Sofinnova Partners, Silvano Spinelli and Gabriella Camboni, which provided the initial seed fund. A seed extension was financed in 2018 by Sofinnova Partners, JDRF T1D fund and the other existing investors.

ENDS

Notes to Editors

About Enthera

Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Companys primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.

The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-establish organ function.

Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca DAddio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Entheras discovery engine and assets are protected by a broad portfolio of patents.

For more information, visit https://www.entherapharmaceuticals.com/

Connect with us on LinkedIn.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.

For more information, please visit: http://www.sofinnovapartners.com

About AbbVie Ventures

AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization.

For more information, please visit http://www.abbvie.com/ventures

For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

About the JDRF T1D Fund

The JDRF T1D Fund is a venture philanthropy fund accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic equity investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance therapeutics, devices, diagnostics and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.

http://www.t1dfund.org

BiovelocITA

BiovelocITA S.r.l. is the first Italian accelerator dedicated to biotech. It was founded by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. Thanks to BiovelocITA, entrepreneurs, scientists and investors can work together to accelerate biotech projects with an international scope and reach the proof of concept that precedes the clinical phase. Set up to offer innovative solutions to the medical community and to patients, BiovelocITA supports the creation and development of innovative biotech companies in all therapeutic areas.

For more information, see: http://www.biovelocita.com

See the original post:
Enthera Pharmaceuticals Raises 28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and Inflammatory Bowel Disease -...

Stem Cell Assay Market Growth Drive by the Rising Diversity of Applications – BioSpace

By Embryonic Stem Cells

TMR Research announces a new report on the global stem cell assay market. The report examines the historical growth trajectory exhibited by the global stem cell assay market and its latest figures, and further provides reliable forecasts for the stem cell assay market based on complete analysis of the markets database. The report also takes a close look at the regional and competitive dynamics of the global stem cell assay market in order to shed light on the dynamics of the global market more clearly. The report is titled Stem Cell Assay Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 2025.

Testing antineoplastic drugs in order to check their potency in cancer treatment has emerged as a major application for the global stem cell assay market. The testing covers impurity, toxicity, and other aspects of the tumors and provides a qualitative and quantitative analysis of various aspects of the tumor. The comprehensive figures provided by stem cell assays has driven the demand from the global stem cell assay market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

The growing diversity of applications of stem cell assays is likely to be a major driver for the global stem cell assay market. Pluripotent stem cells have been used in the treatment of several diseases so far and are likely to remain a key part of the healthcare sector in the coming years due to their intrinsic potential to transform into a wide variety of cells in the human body. This makes them a highly promising research avenue in the treatment of diverse conditions such as Alzheimers, Parkinsons, diabetes, rheumatoid arthritis, and retinal diseases, apart from cancer. The growing prevalence of neurological and neurodegenerative conditions, particularly among the growing geriatric demographic in developed countries, is thus likely to be a major driver for the global stem cell assay market.

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=40&ltype=S

Steady research and development in the medical sector is likely to remain a key driver for the global stem cell assay market, as the diversity of application of stem cells is purely potential until applied to specific avenues. Growing government support to the medical sector is likely to help the global stem cell assay market in this regard, as significant investment is required to carry out advanced medical research.

Regionally, North America and Europe are likely to remain the leading contributors to the global stem cell assay market due to the presence of a stable healthcare sector in developed countries in the region. The ready incorporation of technological advancements such as stem cell assays in the day to day functioning of the healthcare sector is the key driver for the stem cell assay market in developed countries such as the U.S., Canada, the U.K., Germany, and France.

The report also profiles leading players in the global stem cell assay market in order to shed light on the competitive dynamics of the market. Stem cell assay market leaders examined in the report include Thermo Fisher Scientific Inc., GE Healthcare, STEMCELL Technologies Inc., Bio-Rad Laboratories Inc., Hemogenix Inc., Cell Biolabs Inc., and Promega Corporation.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Follow this link:
Stem Cell Assay Market Growth Drive by the Rising Diversity of Applications - BioSpace

→←